ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2420

Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome

Anastasia Dupré1, Juliette Pascaud 1, Elodie Rivière 2, Michael Mingueneau 3, Gaetane Nocturne 4 and Xavier Mariette 5, 1IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, 2IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, 3Biomarker Discovery Platform UTechS CB, Hub de Bioinformatique et biostatistique, C3IB, Institut Pasteur, Paris, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, 5Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cells and flow cytometry, Sjogren's syndrome, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a rare systemic autoimmune disease characterized by a dysregulation of cellular and humoral immunity, leading to a hyper-activation of B cells.

We looked if increase in T follicular helper cells (Tfh) (CD4+PD1+CXCR5+) or T peripheral helper (Tph) cells (CD4+PD1+CXCR5-), as well as cytokines involved in the cross-talk between T and B cells (CXCL-13, soluble CD40L (sCD40L)) could be involved in this B-cell activation.

Methods: We studied two cohorts of patients recruited in the Sjögren reference center of Paris-Sud university (23 controls/29 pSS and 14 controls/18 pSS, respectively). All patients had a diagnosis of pSS according to the ACR/EULAR 2016. Mass cytometry (CYTOF) and flow cytometry were used to quantify circulating cell populations. Cytokines were measured by MULTIPLEX.

Results: We showed a peripheral expansion of Tfh (CD4+PD1+CXCR5+) in patients with pSS compared to controls in flow cytometry and mass cytometry (CYTOF): 5.6 +/- 2.6% vs 3.1 +/- 1.2% (p=0.0005) and 10.2 +/- 5.8% vs 6.3 +/- 3.3% (p=0.0349), respectively. Similarly, patients with pSS had higher blood levels of Tph (CD4+PD1+CXCR5-) with both techniques: 8.0 +/- 4.0% vs 5.4 +/- 3.3% (p=0.0075) and 27.3 +/- 13.8% vs 14.9 +/- 9.3% (p=0.0045), respectively.  Activated Tph assessed by ICOS expression (CD4+PD1+CXCR5-ICOS+) were also higher in pSS patients: 9.6 +/- 7.1% versus 4.4 +/- 3.3% (p=0.0037).
There was a positive correlation between plasmablasts (CD19+CD27+CD38hi) and Tfh levels (r=+0.43, p=0.0015) and Tph levels (r =+0.47, p=0.0004) in CYTOF.            
Patients with pSS also had a trend in favor of a higher level of CXCL13 and soluble CD40L compared to controls: 148.8 +/- 186.2 pg / mL vs 130.5 +/- 207.2 pg / mL (p=0.0846) and 69.9 +/- 70.2 pg / mL mL vs 34.3 +/- 28.2 pg / mL (p=0.0802). There was a positive correlation between Tph and soluble CD40L (r=+0.43, p=0.07) and between activated Tph (CD4+PD1+CXCR5-ICOS+) and CXCL13 (r=+0.64, p< 0.05) in patients with pSS.

Conclusion: Circulating Tfh and Tph T-cell subsets play a role in the hyper-activation of B cells in pSS. Therefore, inhibition of Tfh/Tph function or of cytokines involved in their cross-talk with B cells (CXCL13, CD40L) seems promising therapeutic perspectives in pSS.

Figure 1: Expansion of circulating Tfh cells -a- and Tph cells -b- in patients with primary Sjögren Syndrome versus healthy controls, assessed by mass cytometry. Correlation between circulating Tfh and plasmablasts -c- and circulating Tph and plasmablasts -d-.

Figure 2: Correlation between plasmatic levels of sCD40L and circulating Tph -a- and between plasmatic levels of CXCL-13 and circulating Tph ICOS+ -b- in patients with primary Sjögren Syndrome.


Disclosure: A. Dupré, None; J. Pascaud, None; E. Rivière, None; M. Mingueneau, Biogen, 3; G. Nocturne, None; X. Mariette, Biogen, 2, Bristol-Myers Squibb, 5, GlaxoSmithKline, 5, Janssen, 5, LFB Pharmaceuticals, 5, OSE Immunotherapeutics, 2, Pfizer, 2, 5, UCB Pharma, 5, 8.

To cite this abstract in AMA style:

Dupré A, Pascaud J, Rivière E, Mingueneau M, Nocturne G, Mariette X. Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/role-of-t-follicular-helper-cells-and-t-peripheral-helper-cells-in-the-activation-of-b-cells-in-sjogren-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-t-follicular-helper-cells-and-t-peripheral-helper-cells-in-the-activation-of-b-cells-in-sjogren-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology